Carboranyl thymidine analogues for neutron capture therapy

Werner Tjarks; Rohit Tiwari; Youngjoo Byun; Sureshbabu Narayanasamy; Rolf. F. Barth

doi:10.1039/B707257K

skip RSC | ChemSpider | Feedback

Home > Journals > Chemical Communications > Carboranyl thymidine an...

Authors & Referees | Librarians

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

Chemical Communications

Issue 47, 2007

More about this Journal
Editorial Board
Submit an Article

Follow Journal | |

Journal Home | RSC Journals

Feature Article

Previous Article | Next Article

Carboranyl thymidine analogues for neutron capture therapy

Werner Tjarks , Rohit Tiwari , Youngjoo Byun , Sureshbabu Narayanasamy and Rolf. F. Barth

Chem. Commun., 2007, 4978-4991

DOI: 10.1039/B707257K
Received 14 May 2007, Accepted 17 Jul 2007
First published on the web 15 Aug 2007

Please wait while Download options loads

Request Permissions

Abstract
Cited by
Related Content

Neutron capture therapy (NCT) is a binary radio-chemotherapeutic modality for the treatment of cancer. A major focus of NCT-related research is the development of novel tumor-selective agents that serve as the chemical component in NCT. Thymidine analogues substituted with a boron-containing carborane cluster at the N3 position, designated 3CTAs (3-carboranyl thymidine analogues), constitute one class of these new improved NCT agents. Their chemical, structural and biological properties are discussed in this Feature Article.

Articles By

Werner Tjarks
Rohit Tiwari
Youngjoo Byun
Sureshbabu Narayanasamy
Rolf. F. Barth

Terms & Conditions|Privacy |Accessibility|ACAP Enabled

Chemical Communications

Carboranyl thymidine analogues for neutron capture therapy

Log in (Free Access)

Log in (Subscriber Access)

Articles By